Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q8TDE3
UPID:
RNAS8_HUMAN
Alternative names:
-
Alternative UPACC:
Q8TDE3; B2RPP6; B2RPP7
Background:
Ribonuclease 8, with its low ribonuclease activity, plays a subtle yet significant role in RNA metabolism. This enzyme, encoded by the gene symbolized as Q8TDE3, contributes to the intricate process of RNA degradation and processing, a fundamental aspect of cellular function.
Therapeutic significance:
Understanding the role of Ribonuclease 8 could open doors to potential therapeutic strategies. Its involvement in RNA metabolism suggests a foundational role in cellular biology, offering a promising avenue for drug discovery and therapeutic intervention.